Introduction
============

Sleep problems are a common and important, but poorly understood and under-researched, aspect of chronic obstructive pulmonary disease (COPD). After breathlessness and fatigue, sleep disturbance is considered to be the third most common symptom experienced by people with respiratory disease[@b1-copd-10-293] and is also predictive of exacerbations, respiratory-related emergency hospital visits, and all-cause mortality.[@b2-copd-10-293] Insomnia describes any reported difficulty a person has with sleep[@b3-copd-10-293] and has four elements: difficulties falling asleep, interrupted sleep, trouble staying asleep, and still feeling tired and worn out even after a usual amount of sleep.[@b3-copd-10-293]--[@b5-copd-10-293] Around 10% of the adult population is affected by insomnia, but the occurrence is much higher in people with COPD, where estimates range between 16% and 75%.[@b6-copd-10-293] The benefits of sleep are well known, and long-term interruption of normal sleeping patterns has a detrimental impact on physical, emotional, and social functioning, and is also associated with anxiety, depression, bodily pain, and a wide variety of pre-existing chronic medical conditions.[@b4-copd-10-293] In addition to insomnia, narcolepsy (suddenly falling asleep at inappropriate times), restless legs syndrome, and obstructive sleep apnea are the most common sleep disorders found in the general population,[@b6-copd-10-293] and people with COPD are disproportionately affected. Restless legs syndrome involves a need to move the legs, usually at night-time, is associated with marked sleep disturbance, and affects 7%--14% of the general population and 29% of patients with COPD.[@b7-copd-10-293],[@b8-copd-10-293] Obstructive sleep apnea is the periodic interruption of airflow in the upper airway during sleep and affects 3%--7% of the general population[@b9-copd-10-293] and 25%--29% of people with COPD.[@b10-copd-10-293] A summary of the occurrence of four common sleep disorders in COPD populations is provided in [Table 1](#t1-copd-10-293){ref-type="table"}.[@b8-copd-10-293],[@b11-copd-10-293]--[@b13-copd-10-293]

Given the importance of sleep disorders in COPD, being able to accurately classify their nature and severity is important in the management of COPD. Although self-reported sleep disorders are associated with COPD symptoms and poorer health-related quality of life,[@b14-copd-10-293] their relationship with traditional diagnostic markers of lung function (such as forced expiratory volume in one second, forced vital capacity, and oxygen saturation) is weak.[@b15-copd-10-293] This emphasizes the need for clinical instruments to accurately assess the impact of the disease and its treatment on a patient's health and well-being through patient-reported outcome measures (PROMs)[@b16-copd-10-293],[@b17-copd-10-293] as well as recording changes in physiological function.

Many of the instruments that have measured sleep disturbance in epidemiological studies were originally developed for people with a range of psychological conditions and/or pre-existing sleeping disorders.[@b18-copd-10-293],[@b19-copd-10-293] However, the validity of these measures cannot be assumed to transfer between clinical populations.[@b19-copd-10-293] Thus, the aim of this review was to identify and evaluate the suitability of published measures of sleep disturbance for use in people with COPD in order to make recommendations for best practice for clinical and research purposes. Our objectives were to: Identify which patient-reported outcome sleep measures have been used in people with COPDIdentify which instruments have been developed and validated specifically for people with COPDSummarize the evidence for reliability and validity of sleep instruments in COPD patientsExamine associations with sleep disturbance recorded by sleep instruments used in clinical studies of COPD patients.

Materials and methods
=====================

Ethical approval was not needed to undertake this review, which was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.[@b20-copd-10-293]

Search strategy
---------------

In this study, we conducted a systematic computerized literature review designed to identify all PROMs concerned with sleep problems experienced by people with COPD. The search included all instruments that had been developed and validated in people with COPD as well as generic instruments that had been developed for use in other disease areas and then administered to adult COPD patients.

Stage 1: Identification of sleep outcome measures used in COPD
--------------------------------------------------------------

The first stage of the search was to identify sleep outcome measures that had been used in COPD. This was conducted using EMBASE, MEDLINE, and PsycINFO electronic databases for all years up to May 2014 using both key words, ie, the Medical Subject Headings (MeSH) "COPD" AND "sleep" and expanded to include all recognized subheadings. All titles, abstracts, and full texts from the identified papers were examined by the lead author (APG) for reference to specific sleep instruments or data indicating that at least one sleep outcome measure had been used. A list of sleep outcome measures was then produced. The reference lists and citations of selected articles were also searched to identify any additional sleep PROMs not found by the electronic database search.

Stage 2: Selection and evaluation of sleep instruments used in COPD
-------------------------------------------------------------------

A SCOPUS database search was carried out on each of the detected sleep outcome measures to identify all publications in which the original paper had been cited. The search included the following related terms: Construct-related terms: sleep problemsPopulation terms: COPD patients (in the title, abstract, text, or reference section)Outcome-related terms: development, validation, or psychometric properties of sleep PROMs designed specifically for people with COPD. Sleep outcome measures not specifically designed for people with COPD but used in a COPD patient group whether psychometric data were reported or notMethod-related terms: instrument\* OR measure\* OR question\* OR scale OR assessQuality assessment terms: valid\* or reliab\* or evaluat\* OR psychometric.

We also screened the reference lists and citations of included articles to identify additional relevant publications.

Eligibility criteria
--------------------

To be included in the review, all identified articles had to meet the following inclusion criteria: the article described PROMs that either had been specifically designed and validated for use in patients with COPD or included a generic instrument that had been administered to COPD patients; information on at least one measurement property of the outcome measure was reported; the study sample consisted of adults with a clinical diagnosis of COPD; a full text of the original publication was published electronically, in English, in a peer-reviewed journal.

Articles were excluded if reference to COPD and/or sleep only appeared in the text or reference section. Similarly, we excluded all articles with mixed study samples where the results from COPD patients were not reported separately. Review articles, protocols, and case studies were also excluded. Two investigators (APG and JY) read independently all titles, abstracts, and full texts of all the retrieved articles to determine which were eligible for review. Any disagreements were resolved at a consensus meeting.

Methodological quality assessment
---------------------------------

The COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) checklist[@b21-copd-10-293] is a standardized tool for evaluating the methodological quality of PROMs. COSMIN checklists are used to evaluate the measurement properties of instruments in terms of their internal consistency, reliability, measurement error, content validity, structural validity, hypothesis testing, cross-cultural validity, criterion validity, and responsiveness to change. As it was anticipated that the number of PROMs that had been developed and validated for use in COPD populations was likely to be very small, rather than using the full COSMIN checklist we used four PROM characteristics recommended by the US Food and Drug Administration[@b22-copd-10-293] to evaluate the measurement properties of identified sleep PROM instruments in relation to their use in COPD patients, ie, conceptual and measurement model, reliability, validity, and responsiveness to change.

### Conceptual model

Identified articles were examined for descriptions of concepts contained within the instrument, including the rationale and process for deriving scale scores from raw scores, identifying and dealing with floor and ceiling effects, and scale variability.

### Reliability

Articles were scrutinized for estimates of reliability, including inter-item correlations, test-retest repeatability, internal consistency, and/or kappa statistics.

### Validity

Any reference to content, construct, and criterion-related validity were noted. When considering construct validity, we also recorded methods to differentiate between people with different levels of lung function or disease severity, such as the Global Initiative for Chronic Obstructive Lung Disease staging system that classifies people with COPD according to the results of pulmonary tests. Where available, we also collected data regarding the relationships between sleep outcome instruments and other established COPD outcome measures (such as the St George's Respiratory Questionnaire,[@b23-copd-10-293] the Medical Research Council Dyspnea scale,[@b24-copd-10-293] and routine clinical tests). Any analyses intended to examine dimensionality using factor analysis or Rasch analysis were noted, along with any assessments of differential item functioning that evaluated group differences in PROM item responses.

### Responsiveness to change

All data relating to the ability of the instrument to detect changes over time in terms of sleep disturbance were noted. Where correlations between changes in scores of two measures are reported, these had to relate to predefined hypotheses.

Results
=======

The stage 1 database search identified articles referring to COPD and sleep (Medline 804, EMBASE 2,314, and PsycINFO 59) from which one COPD-specific and six non-disease-specific sleep instruments were identified ([Table 2](#t2-copd-10-293){ref-type="table"}).[@b25-copd-10-293]--[@b31-copd-10-293] In stage 2, the SCOPUS search found 10,602 articles citing any of the seven sleep outcome measures, 270 of which referred to COPD. After applying the exclusion criteria, 44 manuscripts were selected for review ([Figure 1](#f1-copd-10-293){ref-type="fig"}). Nearly 90% of the reviewed publications either used the Pittsburgh Sleep Quality Index (PSQI;[@b30-copd-10-293] 19/44, 43.1%) or the Epworth Sleepiness Scale (ESS; 20/44, 45.5%).[@b28-copd-10-293] The 19-item PSQI measures sleep quality in seven domains and the ESS assesses the likelihood of a person dozing off or falling asleep in eight common life situations. Most studies involved patients with moderate-severe COPD recruited from hospital outpatient or specialist respiratory clinics.

COPD-specific sleep outcome measures
------------------------------------

After assessing the methodological properties of the identified PROMs, only one instrument appeared to have been developed and validated for use in COPD patients, ie, the COPD and Asthma Sleep Impact Scale (CASIS).[@b25-copd-10-293]

The CASIS is a seven-item measure of sleep impairment during the previous week. Five items relate to disturbance falling asleep or staying awake during the day. The remaining two items concern sleep quality. The items are scored on a five-point scale ranging from 0 if the item never applies, to 4 if the item applies very often. A total raw score is produced from the sum of the seven individual scores which is then linearly transformed to a 0--100 total scale score. A mean CASIS score of 43.3±24.7 was reported in patients with mild COPD. The results of the original psychometric testing of the CASIS ([Table 3](#t3-copd-10-293){ref-type="table"}), showed that the scale had good internal consistency (Cronbach's alpha 0.91), test-retest reproducibility (intraclass coefficient 0.84), and concurrent validity (correlated with the St George's Respiratory Questionnaire, *r*=0.68).

None of the non-disease-specific sleep scales reported any tests of reliability or validity to justify their use in the COPD population. Significant associations were observed in only 8/20 (40%) of studies where the ESS was compared with other COPD-related outcome measures. For example, the prevalence of daytime sleepiness (ESS \>10) was significantly greater in patients diagnosed with insomnia.[@b11-copd-10-293] Compared with people who had obstructive sleep apnea/hypopnea syndrome, COPD patients were more likely to be affected by daytime sleepiness.[@b32-copd-10-293] Significant differences in mean ESS scores were observed between patients with COPD and restless legs syndrome compared with controls who had restless legs syndrome.[@b33-copd-10-293] However, no differences in daytime sleepiness were observed in a study that compared use of temazepam between COPD patients and controls.[@b34-copd-10-293] Similarly, no significant differences in ESS scores were detected in patients with and without restless legs syndrome[@b35-copd-10-293] ([Table 4](#t4-copd-10-293){ref-type="table"}).

For the PSQI, significant associations were noted in 11/19 (57.9%) of the relevant studies. PSQI scores were found to be significantly higher in patients with restless legs syndrome.[@b36-copd-10-293] PSQI total scores also correlated with total scores from the St George's Respiratory Questionnaire[@b37-copd-10-293],[@b14-copd-10-293] and the Fatigue Severity Scale.[@b35-copd-10-293] In contrast, no correlation was observed between PSQI and St George's Respiratory Questionnaire scores in an investigation of factors affecting health status in COPD patients with comorbid anxiety or depression.[@b38-copd-10-293] Further, although significant PSQI score reductions were observed in patients receiving a course of cognitive behavioral therapy (where the primary outcome was insomnia),[@b39-copd-10-293] no reductions in pre- and post-sleep quality were observed in a randomized controlled trial that compared cognitive behavioral therapy with usual care, where sleep was a secondary outcome measure to anxiety and depression[@b40-copd-10-293] ([Table 5](#t5-copd-10-293){ref-type="table"}).

[Table 6](#t6-copd-10-293){ref-type="table"} shows the papers that used the four remaining generic outcome measures in studies of COPD patients.[@b33-copd-10-293],[@b35-copd-10-293],[@b41-copd-10-293],[@b42-copd-10-293] With so few studies, there are currently insufficient data to evaluate the utility of these instruments; however, in one study,[@b33-copd-10-293] International Restless Leg Study Group scores correlated significantly with ESS scores.

Although the results provide some evidence of the validity of measures of sleep disturbance in people with COPD, none of the above sleep measures were specifically evaluated for people with COPD. Similarly, we did not find any articles that provided data on test-retest, intrarater, or inter-rater reliability or responsiveness to change among COPD patient groups.

The point estimates of sleep disturbance from clinical studies of COPD patients using the ESS and the PSQI are shown on [Tables 4](#t4-copd-10-293){ref-type="table"} and [5](#t5-copd-10-293){ref-type="table"}. In 13/15 of the studies using the ESS, the mean/median scores were less than 10, ie, below the accepted cutoff value for excessive daytime sleepiness.[@b28-copd-10-293] Most of the observed PSQI scores were above 5, ie, above the cutoff value representing poor quality sleep.[@b30-copd-10-293] Point and upper and lower quartile estimates for the ESS and PSQI are displayed on [Figures 2](#f2-copd-10-293){ref-type="fig"} and [3](#f3-copd-10-293){ref-type="fig"}.

Discussion
==========

Sleep disturbances are an important problem that can seriously impact on physical and mental well-being as well as quality of life for people with COPD. This review identified seven outcome measures that have been used in COPD populations but none has been sufficiently validated to satisfy US Food and Drug Administration requirements to support labeling claims in medical product development. Only one measure, the CASIS, included item response theory modeling when evaluating the psychometric evaluation of the instrument. Incorporating item response theory is now considered to be an essential component in the design and validation of all PROMs.[@b19-copd-10-293]

The majority of sleep studies in COPD have relied on two general measures of sleep dysfunction, the ESS and the PSQI, and although both of these instruments have been extensively used in a variety of clinical populations, neither has been validated for use in COPD patients.

As far as we are aware, this is the first systematic review of sleep measures in COPD. A strength of this study was the comprehensiveness of our literature search. We believe that we have identified all of the main PROMs of sleep disorders that have been used in COPD populations. Nevertheless, as we did not search all electronic databases or carry out a hand search, there is the possibility that we may have missed some relevant articles, particularly those that appeared in non-English language journals. However, by cross-checking the reference lists of all included papers and that of a recent systematic review of instruments designed to measure sleep dysfunction in adults,[@b15-copd-10-293] we believe we have minimized the loss of any important papers.

The review identified only one PROM, ie, the CASIS, which has been specifically designed and validated for use in COPD patients. In each item of the CASIS, patients are advised to "\[...\] think about the impact of breathing problems/COPD/asthma on your sleep during the past week \[...\]" Most items, however, are general in nature and relate to the frequency of symptoms such as falling asleep, staying awake, and waking up feeling rested. Only one item relates specifically to breathing problems, ie, shortness of breath, coughing, and chest tightness. Further, as these symptoms are all contained within the same item, it is not possible to differentiate patients who may have different severity of symptoms; for example, between patients who wake up at night only with shortness of breath or wake up with both shortness of breath and coughing. Since the publication of the original paper, the CASIS has not been used in any intervention studies, so further evidence is needed to confirm the utility of this instrument in guiding the clinical management of COPD patients and in research.

This review has highlighted the current reliance of sleep research on generic sleep measures and the paucity of disease-specific instruments currently available to assess the patient's experience of sleep in relation to COPD. By definition, generic measures tend to cover broad aspects such as functional status and perceptions and are more likely to identify aspects that are not disease-related. Because instruments validated in one population may not perform well in specific populations under investigation, separate validation of generic measures in each population is recommended.[@b43-copd-10-293] Similarly, given that disease-specific measures are generally more responsive to change, outcomes based solely on generic measures are unlikely to detect treatment-related improvements.[@b44-copd-10-293] These deficiencies could call into question findings from previous research on the impact of sleep problems in COPD. The need for validated COPD-specific sleep outcome measures was emphasized in an expert panel meeting held in 2011.[@b45-copd-10-293] While appreciating the multifactorial nature of sleep disturbance in COPD, the panel highlighted the need for an instrument to classify patients according to their night or daytime symptoms, which is not possible using existing PROMs for sleep. Development work on new COPD sleep PROMs to address these limitations is currently being carried out by the authors of this review.

Conclusion
==========

This review highlights the complexity of sleep assessment, the inadequacy of non-disease-specific measures to capture problems experienced by people with COPD, and the absence of robust and validated methods of assessing and classifying symptoms associated with disrupted sleep in COPD. In studies using non-disease-specific sleep measures, there is a pressing need for these to be validated with COPD populations and/or for new disease-specific PROMs to be developed.
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###### 

Summary of the occurrence of common sleep disorders in COPD populations

  Sleep disorder                                                           Author                              Occurrence in COPD
  ------------------------------------------------------------------------ ----------------------------------- --------------------
  Insomnia (chronic sleep disturbance with impaired daytime functioning)   Budhiraja et al[@b11-copd-10-293]   27%
  Excessive sleepiness                                                     Ali Zohal et al[@b12-copd-10-293]   35%
  Restless legs syndrome                                                   Kaplan et al[@b8-copd-10-293]       29%
  Obstructive sleep apnea                                                  McNicholas[@b13-copd-10-293]        1%

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Number of papers found and excluded or included in the review

  Outcome measures                                         SCOPUS references (n)   References to COPD (n)   Excluded   Reviewed
  -------------------------------------------------------- ----------------------- ------------------------ ---------- ----------
  COPD and Asthma Sleep Impact Scale[@b25-copd-10-293]     8                       6                        5          1
  Basic Nordic Sleep Questionnaire[@b26-copd-10-293]       200                     6                        5          1
  Berlin Questionnaire[@b27-copd-10-293]                   720                     22                       21         1
  Epworth Sleepiness Scale[@b28-copd-10-293]               4,720                   153                      133        20
  International Restless Legs Syndrome[@b29-copd-10-293]   548                     4                        3          1
  Pittsburgh Sleep Quality Index[@b30-copd-10-293]         4,144                   71                       52         19
  Sleep Disorders Questionnaire[@b31-copd-10-293]          262                     8                        7          1
  Total                                                    10,602                  270                      226        44

**Abbreviation:** COPD, chronic obstructive pulmonary disease.

###### 

Psychometric properties of COPD and Asthma Sleep Impact Scale

  -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Conceptual and measurement model**   
  Rationale for deriving scale scores    Items generated from focus group discussions in UK and US samples
  Scale structure                        15 item scale scored 1= never to 5= very often -- transferred onto a 0--100 scale
  Variability                            Mean score COPD patients (n=112) 47.1±24.0
  **Reliability**                        
  Inter-intra observer repeatability     Not tested
  Item correlations                      9 items highly correlated *r*\>0.75; 6 items indicating item redundancy
  Internal consistency                   Cronbach's alpha 0.91
  Stability over time                    2-week test-retest repeatability ICC 0.84
  **Validity**                           
  Convergent validity                    Correlated with SGRQ *r*=0.68 *P*=0.0001 Correlations between CASIS scores and number of bad days *r*=0.61, overall health status (0.5), and higher mean CASIS scores in COPD patients receiving oxygen treatment (51.4 vs 43.3) Correlates with living with COPD questionnaire 0.58
  **Responsiveness to change**           Not tested
  -------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** COPD, chronic obstructive pulmonary disease; CASIS, COPD and Asthma Sleep Impact Scale; ICC, intra-class correlation coefficient; SGRQ, St George's Respiratory Questionnaire.

###### 

Summary of studies that used the Epworth Sleepiness Scale

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                             Study focus                                                                                                                                    COPD study sample                                             Measures of COPD severity                                                                                                                   ESS (mean ± SD/median and range)                        ESS \>10 (%)   Associations with ESS score
  ------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------- -------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Aras et al[@b36-copd-10-293]          RLS symptoms in COPD patients during an exacerbation period                                                                                    22 male inpatients                                            GOLD stage IV: FEV~1~ 30% or 50% plus chronic respiratory failure; mean FEV~1~ 39.4%±9.97%                                                  Not reported                                            Not reported   Free thyroxine values negatively correlated with ESS (*r~s~* =−0.481 *P*=0.043)

  Bednarek et al[@b46-copd-10-293]      Prevalence of SDB and COPD in a representative urban sample aged 41--72 years                                                                  676 participants from the electoral register                  FEV~1~/FEV \<0.7, 10.6%                                                                                                                     6.4±3.9                                                 Not reported   Mean ESS in people with excessive sleep disorder: men 12.6±2.0 versus women 12.9±2.4 (*P*\>0.05)

  Budhiraja et al[@b11-copd-10-293]     Prevalence of insomnia in patients with COPD, and characteristics associated with insomnia in COPD patients                                    183 hospital patients                                         GOLD stage I, 3%; stage II, 39%; stage III, 29%; stage IV, 28%; % predicted post-bronchodilator FEV 45.9±18.6. FEV~1~/FVC ratio 49.6±12.5   Not reported                                            Not reported   Daytime sleepiness (ESS \>10) greater in patients with insomnia (36.5% versus 14.6%, *P*=0.004)

  Cavalcante et al[@b35-copd-10-293]    Occurrence and associations with RLS in a COPD population                                                                                      104 hospital outpatient attenders                             mMRC 0 (4.8%); 1 and 2 (48.1%); 3 (34.6%); 4 (12.5%)                                                                                        6.9±5.1                                                 20.2           No difference in mean values between patients without RLS (6.6±4) versus with RLS (7.7±6.0). ESS positively correlated with BMI (*P*\<0.003)

  De Lima et al[@b47-copd-10-293]       Whether clinically stable COPD patients without cognitive symptoms may present with subtle cognitive impairments                               30 hospital outpatients                                       Mean FEV~1~ 42.1±15.9                                                                                                                       6.7±3.7                                                 Not reported   Not reported

  Kapella et al[@b39-copd-10-293]       Feasibility and assessment of the impact of a CBT intervention for people with COPD and insomnia                                               23 patients recruited from advertisements and word of mouth   FEV~1~/FVC ratio \<70% [@b1-copd-10-293]                                                                                                    9.2±5.0                                                 Not reported   Not reported

  Karachaliou et al[@b32-copd-10-293]   Association between OSAHS-related symptoms and physician-diagnosed asthma and COPD                                                             1,501 primary care patients (323 with COPD)                   GOLD stage I, 28.8%; stage II, 53.3%; stage III, 15.2%; stage IV, 2.8%                                                                      Not reported                                            Not reported   Increased odds of people with COPD having an ESS score ≥10; OR 2.04, 95% CI (1.33--3.14)

  Lewis et al[@b48-copd-10-293]         Variability of nocturnal desaturation in COPD over a 3-week period and impact the variability may have on clinical decision-making             26 stable COPD hospital outpatients                           Mean post-bronchodilator FEV~1~ 28.6%                                                                                                       4.1±6.2; range 0--11                                    Not reported   Not reported

  Lewis et al[@b49-copd-10-293]         Prevalence and clinical impact of nocturnal desaturation in a typical outpatient population with COPD                                          59 COPD outpatients                                           Mean predicted FEV~1~ 37.2±14.9; FVC 1.9 ±0.9; FVC predicted 62.1±17.6; TB90% 38.4±34.9                                                     5.0; range 2.0--8.0                                     Not reported   No significant difference between desaturators and nondesaturators (*P*=0.88)

  Lo Coco et al[@b33-copd-10-293]       Prevalence, severity, and associations with RLS in COPD patients                                                                               87 COPD outpatients                                           GOLD stage II, 42.5%; stage III, 40.2%; stage IV, 17.3%                                                                                     8.98±3.89                                               Not reported   Significant difference in mean ESS score between COPD with RLS and controls with RLS 11.81±1.09 versus 8.62±3.66 (*P*=0.009)

  McNicholas et al[@b50-copd-10-293]    Placebo-controlled, double-blind trial of severe, stable COPD patients comparing the effect of tiotropium on sleeping oxygen saturation        56 hospital outpatients                                       FEV~1~ \<65% predicted; FEV~1~/FVC \<70%; Awake paO~2~ \<9.98 kPa (75 mmHg) prior to entry                                                  5.7 in intervention group versus 6.4 in control group   Not reported   None reported

  Nunes et al[@b51-copd-10-293]         Sleep quality in COPD patients at home using actigraphy and association between sleep quality and daytime somnolence                           26 hospital patients                                          GOLD stage II, 50%; stage III, 3 8.5%; stage IV, 11.5%; FEV~1~% predicted 47.62±16.04                                                       8.27±4.4                                                61.5           No difference between COPD and controls (8.27±4.4 versus 6.07±3.9, *P*=0.12). No difference in proportion with ESS ≥10 COPD (61% versus controls 86%; *P*=0.09)

  Oliveira et al[@b52-copd-10-293]      Evaluate accuracy of a portable monitoring device in detection of OSA in patients with COPD                                                    26 hospital outpatients                                       FEV~1~/FVC 0.6±0.10; FEV~1~ (%) post-BD 55±0.08; FVC (%) post-BD 77±8.9                                                                     10.5±4.1                                                Not reported   None reported

  Scharf et al[@b53-copd-10-293]        Correlation between disturbed sleep and COPD                                                                                                   180 pulmonary clinic patients                                 GOLD stage I, 10.6%; stage II, 3 0.6%; stage III, 46.1%; stage IV, 12.8%. FEV~1~ % predicted 47.6±15.2                                      7.0±4.8                                                 24.7           No associations with ESS and other symptoms

  Soriano et al[@b54-copd-10-293]       Natural history of the most common respiratory chronic conditions, including COPD and OSA                                                      500 primary care patients                                     GOLD stage I (27%); stage II (58%); stage III (15%)                                                                                         Not reported                                            29.2           None reported

  Stege et al[@b34-copd-10-293]         Effects of long-term use of a benzodiazepine (temazepam) on breathing, dyspnea, and gas exchange during sleep, sleep quality, and sleepiness   14 respiratory clinic patients                                FEV~1~ % predicted 33.5±9.2; FEV~1~/FVC% 32.7±13.0; FEV~1~ (L) 0.99 ±0.30                                                                   6.0±4.0                                                 50.0           No difference between temazepam (5.0±4.0) and controls (6.0±4.0; *P*=0.13)

  Toraldo et al[@b55-copd-10-293]       Pattern of daytime clinical variables that distinguish desaturator patients from nondesaturator COPD patients using cluster analysis           51 consecutive hospital patients                              FEV~1~ % predicted 53 (SE 1.5); FEV~1~/FVC ratio 37.6 (SE 0.5); FVC % predicted 81.5 (SE 1.2); AHI 2.8 (SE 0.1).\                           3.9 (SE ±0.1)                                           None           No difference between desaturators and nondesaturators, both 3.8 (± SE 0.4)
                                                                                                                                                                                                                                                     Daytime paO~2~ values 60--70 mmHg                                                                                                                                                                                  

  Toraldo et al[@b56-copd-10-293]       Effect of regular use of nCPAP in patients with overlap syndrome                                                                               12 hospital outpatients                                       FEV~1~ (%) 60.3±1.3; FEV~1~/FVC (%) 69.5±0.7                                                                                                16.58±0.86                                              Not reported   Reductions in ESS score between baseline and 3 months (16.6±0.86 versus 11.7±0.46; *P*=0.0001); 3 months and 12 months (11.7±0.46 versus 5.7±0.4; *P*=0.0001), and 12 and 24 months (5.67±0.4 versus 4.75±0.49; *P*=0.033)

  Trauer et al[@b57-copd-10-293]        Relationship between 24-hour oximetry and resting partial pressure of oxygen                                                                   35 community-living patients                                  GOLD stage II, 20%; stage III, 4 9%; and stage IV, 31%; FEV~1~ % predicted 37.5±13.2                                                        Median 4 (IQR 2, 8)                                     Not reported   Negative correlation between ESS and time below 90% SpO~2~ −24 hours −0.18 (0.29); waking hours −0.13 (0.46); sleeping hours −0.17 (0.24)

  Tsolaki et al[@b58-copd-10-293]       Effect of non-invasive ventilation as an additional treatment for severe COPD patients                                                         24 hospital outpatients                                       FEV~1~ (%) 34.7±11.3; FVC (%) 50.8±15.7                                                                                                     9.2±3.7                                                 Not reported   Significant reductions in ESS score between baseline and 1 month in patients who received noninvasive ventilation (10.3 versus 4.9; *P*=0.0001). ESS was an independent predictor of the Mental Component Score of the SF-36 (*P*\<0.001)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** AHI, apnea-hypopnea index; BD, bronchodilator; BMI, body mass index; CI, confidence interval; OR, odds ratio; COPD, chronic obstructive pulmonary disease; RLS, restless legs syndrome; SDB, sleep-disordered breathing; CBT, cognitive behavioral therapy; OSAHS, obstructive sleep apnea/hypopnea syndrome; mMRC, modified Medical Research Council Dyspnoea scale; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; GOLD, Global initiative for chronic Obstructive Lung Disease; SpO~2~, oxygen saturation; ESS, Epworth Sleepiness Scale; SE, standard error; pO~2~, oxygen partial pressure; paO~2~, arterial oxygen tension; IQR, interquartile range; TB90%, time spent with saturation below 90%; SF-36, Short-Form 36 Health Survey; nCPAP, nasal continuous positive airway pressure; SD, standard deviation; OSA, obstructive sleep apnea.

###### 

Summary of papers that used the Pittsburgh Sleep Quality Index

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                               Study focus                                                                                                                                                                                                     COPD study sample                                                                                           Measures of COPD severity                                                                                                                                                 PSQI (mean ± SD)                  PSQI \>5 (%)   Associations with PSQI score
  --------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------- -------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Akinci and Yildirim[@b37-copd-10-293]   Associations between quality of life and breathlessness, fatigue, sleep quality, and FEV~1~ % predicted in patients with COPD                                                                                   79 stable hospital outpatients                                                                              FEV~1~ (%) 51.5±16.1 (range 18--80); FEV~1~/FVC (%) 63.4±9.3 (range 34.6--70.2)                                                                                           7.1±3.9                           Not reported   Correlations between SGRQ and PSQI total scores (0.428, *P*\<0.001); daytime dysfunction (0.400, *P*\<0.001); sleep disturbance (0.481, *P*\<0.001), habitual sleep efficiency (0.271, *P*\<0.05); sleep latency (0.309, *P*\<0.01); subjective sleep quality (0.421, *P*\<0.001) but not sleep duration or use of sleep medication

  Aras et al[@b36-copd-10-293]            RLS symptoms in COPD patients during an exacerbation                                                                                                                                                            22 male inpatients                                                                                          GOLD stage IV: FEV~1~ 30% or 50%, plus chronic respiratory failure; mean FEV~1~ 39.4%±9.97%                                                                               6.0±3.81                          Not reported   PSQI score was higher in patients with RLS symptoms (7.76±3.74) compared with patients without RLS symptoms (3.44±2.18; *P*\<0.05)

  Cavalcante et al[@b35-copd-10-293]      Occurrence and associations with RLS in a COPD population                                                                                                                                                       104 hospital outpatients                                                                                    mMRC 0 (4.8%); 1 and 2 (48.1%); 3 (34.6%); 4 (12.5%)                                                                                                                      7.6 ±4.3                          59.6%          PSQI correlated with Fatigue Severity Scale (*P*\<0.005). Patients with RLS had poor quality sleep (*P*\<0.002). PSQI score correlated with mMRC (*P*\<0.005); higher BMI (*P*=0.01); serum ferritin (*P*=0.005). mMRC and creatinine influenced PSQI sleep quality

  Hynninen et al[@b38-copd-10-293]        Factors affecting health status in COPD patients with comorbid anxiety or depression                                                                                                                            58 hospital outpatients/responders to newspaper advertisements                                              29 (50%) had mild-moderate COPD and 29 (50%) had severe/very severe COPD.\                                                                                                Men 8.1±3.6; women 9.2±3.8        Not reported   PSQI total scores not correlated with SGRQ.\
                                                                                                                                                                                                                                                                                                                                                                      Mean FEV~1~ 53.79±23.96; 50% had FEV~1~ ≥50%                                                                                                                                                                               PSQI daytime functioning correlated with SGRQ total (0.57, *P*≤0.001); symptoms (0.374, *P*≤0.01); activity (0.364, *P*\<0.01); impact (0.56, *P*≤0.001).\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 PSQI sleep disturbance correlated with SGRQ total (0.404 *P*≤0.01); symptoms (0.378, *P*\<0.01), and impact (0.409, *P*≤0.01)

  Hynninen et al[@b40-copd-10-293]        Effect of CBT on anxiety and depression compared with usual care and associations with age and sex                                                                                                              25 hospital patients/respondents to newspaper advertisements                                                FEV~1~ (%) 59.8±21.1                                                                                                                                                      9.8±4.4                           Not reported   No significant difference between pre- and post-treatment sleep quality or at 6 months follow-up as a result of the CBT intervention

  Ito et al[@b59-copd-10-293]             Prevalence and associations between depression and sleep disorders in COPD patients and whether depression and sleep disorders are risk factors for exacerbations, hospitalization, and mortality due to COPD   85 hospital patients                                                                                        GOLD stage I, 21.2%; stage II, 38.8%; stage III, 28.2%; stage IV, 11.8%. Mean post-BD FEV~1~ 1.6±0.7 L; FVC 3.3±0.9 L; FEV~1~/FVC % 47.1±13.9                             5.5±3.3                           43.5%          PSQI scores higher in COPD versus non-COPD patients (5.5±3.3 versus 4.1±2.6; *P*=0.0076). An increase in RR in patients with COPD versus non-COPD controls (RR 1.82, 95% CI 1.03--3.22; *P*=0.042). A weak correlation between PSQI scores and CESD scores (*r*=0.22; *P*=0.044). Annual number of exacerbations was higher in COPD patients with depression (3.3±3.5) compared with patients having sleep problems alone

  Kapella et al[@b39-copd-10-293]         Feasibility and impact of a CBT intervention for people with COPD and insomnia                                                                                                                                  23 patients recruited from advertisements and word of mouth                                                 FEV~1~/FVC ratio \<70% predicted.\                                                                                                                                        11.0±3.6                          Not reported   PSQI scores reduced following COPD treatment (11.0±3.6 versus 6.5±3.4; *P*=0.0002). Within group effect size 1.02
                                                                                                                                                                                                                                                                                                                                                                      Mean FEV~1~ % predicted 62±18; mean FEV~1~/FVC 50±10                                                                                                                                                                       

  Lewis et al[@b48-copd-10-293]           Variability of nocturnal desaturation in COPD as measured by OPO and the impact the variability may have on clinical decision-making                                                                            26 stable hospital outpatients                                                                              Mean FEV~1~ % 28.6±10.6                                                                                                                                                   Not reported                      Not reported   No significant association between PSQI and resting pO~2~ (*P*=0.89)

  Lewis et al[@b49-copd-10-293]           Prevalence and clinical impact of nocturnal desaturation in COPD outpatients                                                                                                                                    59 consecutive outpatient and pulmonary rehabilitation patients                                             FEV~1~ \<60% predicted and FEV~1~/FVC \<70% predicted; mean FEV~1~ % predicted 37.2±14.9; mean FVC % predicted 37.2±14.9; mean FEV~1~ 0.9±0.4 L                           Median 7 (IQR 4, 11)              61%            No significant difference in PSQI total score between desaturators and nondesaturators (8 \[IQR 4, 11\] versus 7 \[IQR 4, 11\]; *P*=0.63)

  Nisbet et al[@b60-copd-10-293]          Occurrence of overnight desaturation; if resting oxygen saturation predicts overnight desaturation and whether desaturation correlates with HRQoL and sleep quality                                             38 consecutive outpatient and pulmonary rehabilitation patients                                             FEV~1~ \<60% predicted and FEV~1~/FVC ratio \<70% predicted.\                                                                                                             7.1±3.99                          Not reported   No significant difference in PSQI total score between desaturators and nondesaturators (6.7±3.78 versus 7.1±3.99; *P*=0.82)
                                                                                                                                                                                                                                                                                                                                                                      Mean FEV~1~ (L) 0.8±0.37; mean FVC (L) 2.1±0.65                                                                                                                                                                            

  Nunes et al[@b14-copd-10-293]           Impact of sleep quality on HRQoL in COPD                                                                                                                                                                        30 hospital COPD patients                                                                                   GOLD stage II, 50.0%; stage III, 33.3%; stage IV, 16.7%; mean FEV~1~% predicted 48.55±17.27 FEV~1~/FVC % 52.11±9.85                                                       7.37±3.6                          70.0%          Significant positive correlation between PSQI total score and SGRQ total score (*r*=0.42; *P*=0.02) and impact domain score (*r*=0.47; *P*=0.01); global PSQI score was a predictor of SGRQ total score (adjusted *r*^2^ 0.373, *P*=0.001) and SGRQ impact score (adjusted *r*^2^ 0.329, *P*=0.001)

  Nunes et al[@b51-copd-10-293]           Sleep quality in COPD patients at home using actigraphy and association between sleep quality and daytime somnolence                                                                                            26 stable respiratory outpatients                                                                           GOLD stage II, 50%; stage III, 38.5%; stage IV, 11.5%; mean FEV~1~ % predicted 47.62±16.04                                                                                6.96±3.5                          57.7%          Mean PSQI total score significantly worse in COPD than in controls (6.96±3.5 versus 4.8±2.4; *P*=0.043); no significant correlation between PSQI and actigraphy variables

  Oh et al[@b61-copd-10-293]              Characteristics of fatigue in patients with chronic lung disease                                                                                                                                                128 hospital patients, 80% of whom had COPD, 13% had bronchiectasis, and 4% had interstitial lung disease   Mean FEV~1~ 64.5±28.8                                                                                                                                                     Mean score 1.9±0.7 (range 0--3)   Not reported   In the regression analysis, sleep quality was not independently associated with fatigue; standardized β coefficient 0.02: *t*=0.25 *P*=0.8

  Reishtein[@b62-copd-10-293]             Impact of dyspnea, fatigue, and sleep difficulty on functional performance                                                                                                                                      30 home and 47 clinic patients                                                                              FEV~1~ \<60% predicted; mean FEV~1~ 41.2±11.79                                                                                                                            8.69±4.33                         Not reported   Weak non-significant correlation between sleep difficulty and functional performance (−0.17, *P*\>0.05)

  Scharf et al[@b53-copd-10-293]          Extent of sleep problems in COPD; predictors of HRQoL and the contribution of sleep disturbance to HRQoL                                                                                                        180 pulmonary clinic patients                                                                               GOLD stage I, 10.6%; stage II, 30.6%; stage III, 46.1%; stage IV, 12.8%; mean FVC% predicted 64.7±16.3; FEV~1~/FVC % 57.5 ±12.3; FEV~1~ (L) 1.24±0.50 FVC (L) 2.17±0.70   11.0±5.4                          77.7           HRQoL and SGRQ scores significantly associated with PSQI (adjusted *r*^2^ HRQoL 0.24 and SGRQ 0.23 both *P*\<0.0001). HRQoL and SGRQ were independently associated with PSQI score (*r*^2^ 0.06, *P*=0.0002 and *r*^2^ 0.05, *P*=0.0005, respectively)

  Suh et al[@b63-copd-10-293]             Effect of anxiety on heart rate variability, depression, and sleep in COPD                                                                                                                                      30 COPD pulmonary rehabilitation patients and 30 non-COPD controls                                          COPD patients with anxiety PSQI 12.0 (4.06) versus healthy patients with anxiety 7.8 (4.02) GOLD criteria: stage I, 13.3%; stage 2, 43.3%; stage 3, 30%; stage 4, 13.3%   12.0±4.02                         Not reported   COPD patients with anxiety had poorer sleep quality than non-COPD controls with anxiety (12.0 versus 7.8; *t*=2.74, *P*=0.01). The COPD only group had significantly lower PSQI scores than COPD anxiety group (6.9 versus 12.0; *t*=−3.49, *P*=0.002)

  Soler et al[@b64-copd-10-293]           PR improves sleep quality in chronic lung disease                                                                                                                                                               46 obstructive\                                                                                             FEV~1~ % predictive\                                                                                                                                                      6.6 (3.9) obstructive\            58             Poor sleep quality was reported by 58% of patients before PR and 47% after PR (*P*\<0.001)
                                                                                                                                                                                                                                                          13 restrictive\                                                                                             Obstructive 44.2 (12.3)\                                                                                                                                                  8.2 (3.7) restrictive\                           
                                                                                                                                                                                                                                                          5 mixed                                                                                                     Restrictive 82.2 (6.8)\                                                                                                                                                   6.6 (4.7) mixed                                  
                                                                                                                                                                                                                                                                                                                                                                      Mixed 62.7 (11.5)                                                                                                                                                                                                          

  Halvani et al[@b65-copd-10-293]         Evaluation of exogenous melatonin administration in improvement of sleep quality in patients with COPD                                                                                                          48 stable hospital patients                                                                                 Confirmed diagnosis of GOLD stage II, GOLD stage IV                                                                                                                       Intervention 11.63±3.96\          Not reported   Melatonin group\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Controls 10.66±2.48                              Baseline 11.63±3.96; follow-up 8.7±4.15 (*P*=0.002).\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Placebo group\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Baseline 10.66±2.48; follow-up 10.11±2.66 (*P*=0.065)

  Bhatt et al[@b66-copd-10-293]           NPPV in subjects with stable COPD                                                                                                                                                                               15 stable hospital patients who received NPPV versus 12 controls                                            FEV~1~/FVC ratio \<0.70 PaCO~2~ \<52 mmHg                                                                                                                                 3.7 (3.0) NPPV\                   Not reported   Results after 6 months\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                6.1 (3.2) Controls                               NPPV 3.7 (3.0) versus 3.4 (2.0; *P*=0.2)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 Controls\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 6.1 (3.3) vs 5.7 (3.2) *P*=0.77
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BMI, body mass index; CI, confidence interval; COPD, chronic obstructive pulmonary disease; RLS, restless legs syndrome; mMRC, modified Medical Research Council Dyspnea scale; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; GOLD, Global initiative for chronic Obstructive Lung Disease; IQR, interquartile range; nCPAP, nasal continuous positive airway pressure; PR, pulmonary rehabilitation; RR, relative risk; BD, bronchodilator; CBT, cognitive behavioral therapy; SD, standard deviation; NPPV, noninvasive positive pressure ventilation; PaCO~2~, partial pressure of carbon dioxide; HRQoL, health-related quality of life; PSQI, Pittsburgh Sleep Quality Index; OPO, overnight pulse oximetry; SGRQ, St George's Respiratory Questionnaire; CESD, Center for Epidemiologic Studies-Depression.

###### 

Summary of articles using generic sleep measures

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome measure and authors                               Study focus                                                                                          COPD study sample                          Measures of COPD severity                                                                                                                                                                       Outcome reported (mean ± SD)                         Associations
  --------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Berlin Questionnaire Cavalcante et al[@b35-copd-10-293]   Occurrence and associations with RLS in a COPD population                                            104 hospital outpatient attenders          mMRC 0 (4.8%); 1 and 2 (48.1%); 3 (34.6%); 4 (12.5%)                                                                                                                                            30 (29%) of patients had a high probability of OSA   Risk of OSA not associated with RLS (*P*=0.25)

  BNSQ Saaresranta et al[@b41-copd-10-293]                  Sleep quality and excessive daytime sleepiness in ambulatory patients with moderate to severe COPD   15 consecutive female clinic outpatients   FEV~1~ predicted \<65% of daytime hypoxemia (PaO~2~ \<10.0 kPa) and/or hypercapnia (PaCO~2~ \>6.0 kPa); FEV~1~ % 36±12; FVC % 63±14; FEV~1~ (L) 0.73±0.45 (range 0.25--1.8); FVC (L) 1.3±0.45   BNSQ 9.9±3.0                                         BNSQ score higher than controls (9.9±3.0 versus 7.6±3.2; *P*=0.025) and correlated with insulin levels (*r*=0.59, *P*=0.027) and body movements (*r*=0.52, *P*=0.047)

  IRLSG Lo Coco et al[@b33-copd-10-293]                     Prevalence, severity, and associations with RLS in COPD patients                                     87 COPD outpatients                        GOLD stage II, 42.5%; stage III, 40.2%; stage IV, 17.3%                                                                                                                                         IRLSG score 32 (36.8%)                               IRLSG score in COPD patients 20.5±2.8 versus 18.0±3.5 in controls (*P*=0.016); moderate correlation between ESS and IRLSG score (Spearman correlation 0.489, *P*=0.01)

  SDQ Valipour et al[@b42-copd-10-293]                      Differences in symptoms and polysomnographic parameters in COPD patients                             52 consecutive hospital outpatients        FEV~1~% predicted 60±10; FVC % predicted 93±12; FEV~1~/FVC 60±8                                                                                                                                 SA 36.0±6.9\                                         COPD patients had higher scores in PLM (25.2±7.1 versus 21.1±6.2, *P*=0.0003) and PSY (18.0±6.0 versus 15.3±5.0, *P*=0.035)\
                                                                                                                                                                                                                                                                                                                                                                                                            PLM 25.2±7.1\                                        Minimum SaO~2~ had an independent effect on SDQ subscale scores: SA (*P*=0.045), PLM (*P*=0.051), PSY (*P*=0.037), and narcolepsy (*P*=0.053) Mean overnight SaO~2~ was a significant predictor of PSY score (*P*=0.015)
                                                                                                                                                                                                                                                                                                                                                                                                            PSY 18.0±6.0\                                        
                                                                                                                                                                                                                                                                                                                                                                                                            Narcolepsy 22.1±5.5                                  
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BNSQ, Basic Nordic Sleep Questionnaire; COPD, chronic obstructive pulmonary disease; PLM, periodic limb movement; SDQ, Sleep Disorders Questionnaire; PSY, psychiatric sleep disorder; RLS, restless leg syndrome; IRLSG, International Restless Leg Study Group; SA, sleep apnea; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 second; OSA, obstructive sleep apnea; mMRC, modified Medical Research Council Dyspnea scale; GOLD, Global initiative for chronic Obstructive Lung Disease; SaO~2~, arterial oxygen saturation; ESS, Epworth Sleepiness Scale; PaCO~2~, partial pressure of carbon dioxide; PaO~2~; hypercapnia PaCO.
